Cargando…

Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era

Coronavirus infection is a pandemic threat and the most dangerous disease of the 21(st) century. Despite the rigorous exertion of world-class researchers, there is no perfect cure for it. It has been seen in presently available studies that Paxlovid prevents the progression of diseases and reduces s...

Descripción completa

Detalles Bibliográficos
Autores principales: Niraj, Niraj, Mahajan, Sonia Shinde, Prakash, Ajay, Sarma, Phulen, Medhi, Bikash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043822/
https://www.ncbi.nlm.nih.gov/pubmed/36722557
http://dx.doi.org/10.4103/ijp.ijp_291_22
_version_ 1784913235453935616
author Niraj, Niraj
Mahajan, Sonia Shinde
Prakash, Ajay
Sarma, Phulen
Medhi, Bikash
author_facet Niraj, Niraj
Mahajan, Sonia Shinde
Prakash, Ajay
Sarma, Phulen
Medhi, Bikash
author_sort Niraj, Niraj
collection PubMed
description Coronavirus infection is a pandemic threat and the most dangerous disease of the 21(st) century. Despite the rigorous exertion of world-class researchers, there is no perfect cure for it. It has been seen in presently available studies that Paxlovid prevents the progression of diseases and reduces severity in patients tremendously who are at high risk of hospitalization and death. It is a safe oral antiviral drug and has the potential to treat infections from multiple corona variants including omicron which affects humans. Paxlovid is comparatively less expensive than other available effective medicines. Consequently, it reduces hospitalization and death and helps to plummet the economic burden on patients and the health-care system globally. This medicine is still under investigation, and numerous clinical trials are still underway. Its potential side effects are minor and well tolerated by research study participants. Studies show its benefits outweigh the risk, and it is an effective and good alternative for the treatment of coronavirus disease.
format Online
Article
Text
id pubmed-10043822
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-100438222023-03-29 Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era Niraj, Niraj Mahajan, Sonia Shinde Prakash, Ajay Sarma, Phulen Medhi, Bikash Indian J Pharmacol Short Communication Coronavirus infection is a pandemic threat and the most dangerous disease of the 21(st) century. Despite the rigorous exertion of world-class researchers, there is no perfect cure for it. It has been seen in presently available studies that Paxlovid prevents the progression of diseases and reduces severity in patients tremendously who are at high risk of hospitalization and death. It is a safe oral antiviral drug and has the potential to treat infections from multiple corona variants including omicron which affects humans. Paxlovid is comparatively less expensive than other available effective medicines. Consequently, it reduces hospitalization and death and helps to plummet the economic burden on patients and the health-care system globally. This medicine is still under investigation, and numerous clinical trials are still underway. Its potential side effects are minor and well tolerated by research study participants. Studies show its benefits outweigh the risk, and it is an effective and good alternative for the treatment of coronavirus disease. Wolters Kluwer - Medknow 2022 2023-01-31 /pmc/articles/PMC10043822/ /pubmed/36722557 http://dx.doi.org/10.4103/ijp.ijp_291_22 Text en Copyright: © 2023 Indian Journal of Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Short Communication
Niraj, Niraj
Mahajan, Sonia Shinde
Prakash, Ajay
Sarma, Phulen
Medhi, Bikash
Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era
title Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era
title_full Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era
title_fullStr Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era
title_full_unstemmed Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era
title_short Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era
title_sort paxlovid: a promising drug for the challenging treatment of sars-cov-2 in the pandemic era
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043822/
https://www.ncbi.nlm.nih.gov/pubmed/36722557
http://dx.doi.org/10.4103/ijp.ijp_291_22
work_keys_str_mv AT nirajniraj paxlovidapromisingdrugforthechallengingtreatmentofsarscov2inthepandemicera
AT mahajansoniashinde paxlovidapromisingdrugforthechallengingtreatmentofsarscov2inthepandemicera
AT prakashajay paxlovidapromisingdrugforthechallengingtreatmentofsarscov2inthepandemicera
AT sarmaphulen paxlovidapromisingdrugforthechallengingtreatmentofsarscov2inthepandemicera
AT medhibikash paxlovidapromisingdrugforthechallengingtreatmentofsarscov2inthepandemicera